A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo

Ashwani Rajput, Alan P. Koterba, Jeffrey L. Kreisberg, Jason M. Foster, James K V Willson, Michael G. Brattain

Research output: Contribution to journalArticlepeer-review

41 Scopus citations


Epidermal growth factor receptor (EGFR) is widely expressed in a number of solid tumors including colorectal cancers. Overexpression of this receptor is one means by which a cell can achieve positive signals for survival and proliferation; another effective means is by constitutive activation of EGFR. We have elucidated the role of constitutive EGFR signaling in malignant progression by stably transfecting colon cancer cells with a human transforming growth factor-α cDNA (a ligand for EGFR) under repressible control by tetracycline. We show that constitutive expression of transforming growth factor-α and its subsequent constitutive activation of EGFR allows for cancer cell survival in response to environmental stress in vitro and in vivo as well. The reversal of constitutive EGFR activation results in the loss of downstream mitogen-activated protein kinase and Akt activation, and a reduction in xenograft size that is associated with decreased proliferation and increased apoptosis. We used CI-1033, a small molecule antagonist of EGFR, to dissect an activation pathway that shows the ability of ERBb2 to activate Akt, but not Erk in the face of EGFR antagonism. This novel escape mechanism is a possible explanation of why anti-EGFR therapies have shown disappointing results in clinical trials.

Original languageEnglish (US)
Pages (from-to)665-673
Number of pages9
JournalCancer research
Issue number2
StatePublished - Jan 15 2007

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'A novel mechanism of resistance to epidermal growth factor receptor antagonism in vivo'. Together they form a unique fingerprint.

Cite this